Pancreatic Cancer – Opportunity Analysis and Forecasts to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.
The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in treatment guidelines across the 8MM. CP-613 (devimistat) is the lead pipeline candidate in 1L setting. This indication will also se introduction of 2 strong pipeline agents in 3L setting.
KEY QUESTIONS ANSWERED
• Nine late-stage pipeline agents are going to enter the pancreatic cancer market from 2019 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in pancreatic cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
• What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
• What are the main corporate trends? Who are the current and future players?
Scope
Overview of pancreatic cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline pancreatic cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting pancreatic cancer therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
Analysis of the current and future market competition in the global pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
Among the late-stage pipeline products and marketed agents, CP-613 (devimistat) and Masiviera (masitinib) are expected to generate the greatest revenues over the forecast period.
The most important unmet needs in the pancreatic cancer market include: effective treatment options that prolong survival in advanced or metastatic settings, early diagnosis and tumor targeting drugs with novel mechanisms of actions.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global pancreatic cancer therapeutics market from 2019-2029.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
OSI Pharmaceuticals
Merrimack Pharmaceuticals / Baxalta
Bayer
Loxo Oncology
Ipsen Pharma
Celgene
Taiho
Biogene
AstraZeneca
Merck & Co
Pfizer
Erytech
Rafael
Eleison
AB Science
FibroGen
Tyme
Corcept
Tella
Mateon/Oncotelic
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.